List view / Grid view

Issue #4 2017

Artificial intelligence in drug discovery: how long before we see the real impact?

14 December 2017 | By Richard Goodwin

A new race is well underway involving big pharma and big data companies to see who can most effectively mine the new massive data using artificial intelligence (AI). The aim: reducing costs by using targeted in silico analysis, reducing in vitro and in vivo screening, and reviewing huge quantities of…

Proteogenomics research – on the frontier of precision medicine

article

Proteogenomics research – on the frontier of precision medicine

14 December 2017 | By Alicia Landeira, Javier Carabias, Jonatan García, Manuel Fuentes (Cancer Research Centre), Maria Gonzalez-Gonzalez, Paula Díez (Cancer Research Centre), Rafael Góngora, Rodrigo Garcia-Valiente

Proteogenomics is the systematic and comprehensive integration of proteomics with genomics and transcriptomics. Proteogenomics is opening new hallmarks in biomedical research. Recently, several studies have demonstrated the relevance of proteogenomics in cancer research. This article provides a brief review of the advantages of proteogenomics in precision medicine.

article

Expert view: Conquering late stage failures with advanced hit-to-lead techniques

14 December 2017 | By Steven G Jarvis (Head of Pharma & Biotech Segment Strategy - MilliporeSigma)

Failing early in drug discovery is the primary driving force for new techniques in the hit-to-lead phase.

Identification of hits and leads for human African trypanosomiasis

article

Identification of hits and leads for human African trypanosomiasis

13 December 2017 | By Dr Sheraz Gul, Giulia Pasini, Maria Paola Costi

Neglected tropical diseases (NTD) affect more than one billion people and new targets and drugs are needed to tackle these infections. The multi-disciplinary NMTrypI consortium has identified a number of different compound classes which could be effective against these diseases. This article reviews some of these compounds...

article

Informatics infrastructure for public-private collaborations in neglected disease research

13 December 2017 | By Julio Martin

Efforts to develop new medicines for diseases of the developing world (DDW) have been somewhat fragmented in the past and progress has been limited, despite considerable investment. Public-private partnership (PPP) is becoming an essential model for research in neglected disease areas. However, collaboration on this scale presents unique challenges, some…

Patient-derived neural progenitor cells as a drug discovery model for mitochondrial diseases

article

Patient-derived neural progenitor cells as a drug discovery model for mitochondrial diseases

13 December 2017 | By Alessandro Prigione, Carmen Lorenz, Gizem Inak

Mitochondrial DNA (mtDNA) mutations cause severe disorders that are untreatable and mostly affect the nervous system. The difficulty in funding therapies may also be explained by the lack of viable modelling systems...

article

Expert view: Optimising the hit-to-lead workflow

13 December 2017 | By Dr. Paul Wylie (Head of Applications at TTP Labtech)

Hits identified in high-throughput screens are evaluated within the hit-to-lead phase of drug discovery, where they undergo an iterative optimisation process employing a variety of techniques to identify promising lead compounds to move forward to the lead optimisation phase.

Using bioinformatics sequence similarities to optimise repurposing activities

article

Using bioinformatics sequence similarities to optimise repurposing activities

12 December 2017 | By Andrea Zaliani, Dr Sheraz Gul

A significant amount of selectivity and potency data originating from screening of drug targets is generated each year and deposited in public databases. This can be exploited to accelerate drug discovery, in particular, for a variety of repurposing activities...

Machine learning - image of computer circuits in a head

article

Machine learning approaches as tools to accelerate drug discovery

12 December 2017 | By Alexey Zakharov, Anton Simeonov

Computational methods based on machine learning approaches are being introduced increasingly widely to screen the large number of molecules that have never participated in the drug discovery process, but which might have significant drug development potential. This article considers the latest advances in machine learning as applied to drug discovery...

Implementing ADCC assays in QC: When donor variability isn’t an option

article

Q&A: Implementing ADCC assays in QC: when donor variability isn’t an option

12 December 2017 | By Drug Target Review

DiscoverX recently introduced the single donor-derived KILR CD16 Effector Cells to ensure assay reproducibility for screening, characterisation, and QC lot release of antibody drugs.

article

A pragmatic approach to hit validation following biochemical high-throughput screening

12 December 2017 | By Dr Agnes Martin, Dr Laurent Rigoreau, Dr Sheila McLoughlin

Progressing actives from a high-throughput screen (HTS) of a target protein into suitable starting points for lead identification is fraught with pitfalls. The volume and quality of the HTS output is a function of the quality of the screening library, as well as specific properties of both the target and…

article

Expert view: Addressing the big challenges in drug screening

12 December 2017 | By Joesph Zock (Product Managemenr at IntelliCyt)

One of the biggest challenges facing drug discovery across all therapeutic modalities (small molecule, biologics, and cellular) remains the balance between physiological relevance and throughput.

Integrated Drug Discovery Panel – Your questions answered!

article

Q&A: Integrated drug discovery panel – your questions answered

11 December 2017 | By Drug Target Review

Drug discovery from concept to drug candidate has become a collective effort where multi-disciplinary project teams from CROs work with drug companies and academia to deliver clinical candidates, overcoming multi-factorial research obstacles along the way.

article

Expert view: Improving hit-to-lead results

11 December 2017 | By Alan Fletcher (VP and General Manger of Discovery Instruments and Reagents at PerkinElmer)

Declining R&D productivity is a key challenge in the pharmaceutical industry today.

article

Screening In-Depth Focus 2017

11 December 2017 | By Drug Target Review

In this In-Depth Focus on Screening, we look at clinically-oriented phenotypic screening and explore how 3-D bioprinted tissues can be used as disease-in-a-dish models for drug screening.

Cookie	Type	Duration	Description
cookielawinfo-checkbox-advertising-targeting	persistent	1 year	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics	persistent	1 year	This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary	persistent	1 year	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	persistent	1 year	This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID	session	1 year	This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy	persistent	1 year	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged	session	1 year	This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.

Cookie	Type	Duration	Description
advanced_ads_browser_width	persistent	1 month	This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions	persistent	2 years	This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info	persistent	1 month	This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer	persistent	1 year	This cookie is set by Advanced Ads and sets the referrer URL.
bscookie	persistent	2 years	This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE	persistent	2 years	This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr	persistent	3 months	This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory	persistent	1 month	This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE	persistent	5 months	This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.

Cookie	Type	Duration	Description
bcookie	persistent	2 years	This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS	persistent	30 minutes	This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang	session	1 year	This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc	persistent	1 day	This cookie is set by LinkedIn and used for routing.
lissc	persistent	11 months	This cookie is set by LinkedIn share Buttons and ad tags.
vuid	persistent	2 years	We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId	persistent	2 years	This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule	persistent	20 minutes	This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session	persistent	20 minutes	This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues	persistent	20 minutes	This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga	persistent	2 years	This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat	persistent	1 minute	This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid	persistent	1 day	This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.

Cookie	Type	Duration	Description
cf_ob_info	persistent	1 minute	This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob	persistent	1 minute	This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only	session	1 year	This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush	persistent	1 month	This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db	persistent	Until cleared	This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC	session	1 year	This cookie is set by Youtube and is used to track the views of embedded videos.

Recommended

Issue #4 2017